BR112017003705A2 - compostos contendo nitrogênio tricíclicos para o tratamento de infecção por neisseria gonorrhoea - Google Patents

compostos contendo nitrogênio tricíclicos para o tratamento de infecção por neisseria gonorrhoea

Info

Publication number
BR112017003705A2
BR112017003705A2 BR112017003705A BR112017003705A BR112017003705A2 BR 112017003705 A2 BR112017003705 A2 BR 112017003705A2 BR 112017003705 A BR112017003705 A BR 112017003705A BR 112017003705 A BR112017003705 A BR 112017003705A BR 112017003705 A2 BR112017003705 A2 BR 112017003705A2
Authority
BR
Brazil
Prior art keywords
containing compounds
gonorrhoea
treatment
tricyclic nitrogen
neisseria infection
Prior art date
Application number
BR112017003705A
Other languages
English (en)
Other versions
BR112017003705B1 (pt
Inventor
Louisa Widdowson Katherine
Original Assignee
Glaxosmithkline Ip Dev Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Ip Dev Ltd filed Critical Glaxosmithkline Ip Dev Ltd
Publication of BR112017003705A2 publication Critical patent/BR112017003705A2/pt
Publication of BR112017003705B1 publication Critical patent/BR112017003705B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Abstract

resumo ?compostos contendo nitrogênio tricíclicos para o tratamento de infecção por neisseria gonorrhoea? a presente invenção se refere aos métodos para tratar infecção por neisseria gonorrhoeae, os quais compreendem administrar a um sujeito em necessidade dos mesmos novos compostos contendo nitrogênio tricíclicos e composições farmacêuticas correspondentes, conforme descrito neste relatório.
BR112017003705-0A 2014-08-22 2015-08-20 Compostos contendo nitrogênio tricíclicos para o tratamento de infecção por neisseria gonorrhoea BR112017003705B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462040488P 2014-08-22 2014-08-22
US62/040,488 2014-08-22
PCT/IB2015/056325 WO2016027249A1 (en) 2014-08-22 2015-08-20 Tricyclic nitrogen containing compounds for treating neisseria gonorrhoea infection

Publications (2)

Publication Number Publication Date
BR112017003705A2 true BR112017003705A2 (pt) 2017-12-05
BR112017003705B1 BR112017003705B1 (pt) 2022-07-12

Family

ID=54072911

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017003705-0A BR112017003705B1 (pt) 2014-08-22 2015-08-20 Compostos contendo nitrogênio tricíclicos para o tratamento de infecção por neisseria gonorrhoea

Country Status (22)

Country Link
US (2) US10702521B2 (pt)
EP (2) EP3639824A1 (pt)
JP (2) JP6546654B2 (pt)
KR (1) KR20170043603A (pt)
CN (2) CN110403939A (pt)
AR (1) AR101674A1 (pt)
AU (1) AU2015304847B2 (pt)
BR (1) BR112017003705B1 (pt)
CA (1) CA2958800C (pt)
CL (1) CL2017000391A1 (pt)
CO (1) CO2017001658A2 (pt)
CR (1) CR20170069A (pt)
DO (1) DOP2017000049A (pt)
EA (1) EA031589B1 (pt)
ES (1) ES2759303T3 (pt)
IL (1) IL250251A0 (pt)
MX (1) MX2017002321A (pt)
PE (1) PE20170501A1 (pt)
PH (1) PH12017500315A1 (pt)
SG (1) SG11201700566SA (pt)
TW (1) TW201618779A (pt)
WO (1) WO2016027249A1 (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE049547T2 (hu) 2016-06-08 2020-10-28 Acraf Új baktériumellenes szerek
US20200077658A1 (en) 2016-12-16 2020-03-12 Basf Se Pesticidal Compounds
EP3946342A1 (en) * 2019-04-03 2022-02-09 GlaxoSmithKline Intellectual Property Development Limited Gepotidacin for use in the treatment of bacterial urinary tract infections
US20230116403A1 (en) 2019-12-02 2023-04-13 Storm Therapeutics Limited Polyheterocyclic compounds as mettl3 inhibitors
CN115335054A (zh) 2020-04-02 2022-11-11 葛兰素史克知识产权发展有限公司 用吉泊达星治疗淋病奈瑟氏菌的方案
EP4142731A1 (en) * 2020-04-28 2023-03-08 Noorik Biopharmaceuticals AG Treatment of pulmonary complications of coronavirus infections
EP4143188A1 (en) 2020-04-29 2023-03-08 GlaxoSmithKline Intellectual Property Development Limited Crystalline forms of gepotidacin
EP4288035A1 (en) 2021-02-05 2023-12-13 GlaxoSmithKline Intellectual Property Development Limited Oral solid dose formulations
EP4316463A1 (en) 2022-08-02 2024-02-07 GlaxoSmithKline Intellectual Property Development Limited Novel formulation
WO2024068524A1 (en) 2022-09-26 2024-04-04 Glaxosmithkline Intellectual Property Development Limited Gepotidacin for use in the treatment of bacterial prostatitis

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2090767A1 (en) 1992-03-06 1993-09-07 Gerald Guillaumet 1,4-dioxino[2,3-b]pyridine derivatives
DE69423383T2 (de) * 1993-05-13 2000-08-24 American Cyanamid Co Herstellung und Verwendungen von LOS-verminderten Aussenmembran-Proteinen von Gram-negativen Kokken
GB0207450D0 (en) 2002-03-28 2002-05-08 Glaxo Group Ltd Novel compounds
FR2798656B1 (fr) 1999-09-17 2004-12-17 Aventis Pharma Sa Derives de la quinolyl propyl piperidine, leur preparation et les compositions qui les contiennent
EP1306038B1 (en) 2000-07-21 2005-12-21 Ljudmila Petrovna Maljuk Plate for a stand-up meal
DE60125373T2 (de) 2000-07-26 2007-10-18 Smithkline Beecham P.L.C., Brentford Aminopiperidin chinoline und ihre azaisosteren analoga mit antibakterieller wirkung
PL362984A1 (en) 2000-09-29 2004-11-15 Glaxo Group Limited Compounds useful in the treatment of inflammatory diseases
FR2816618B1 (fr) 2000-11-15 2002-12-27 Aventis Pharma Sa Derives heterocyclylalcoyl piperidine, leur preparation et les compositions qui les contiennent
GB0031088D0 (en) 2000-12-20 2001-01-31 Smithkline Beecham Plc Medicaments
EP1345903A1 (en) 2000-12-21 2003-09-24 Ciba SC Holding AG Crystalline forms of cerivastatin sodium
GB0101577D0 (en) 2001-01-22 2001-03-07 Smithkline Beecham Plc Compounds
GB0112836D0 (en) 2001-05-25 2001-07-18 Smithkline Beecham Plc Medicaments
GB0112834D0 (en) 2001-05-25 2001-07-18 Smithkline Beecham Plc Medicaments
GB0118238D0 (en) 2001-07-26 2001-09-19 Smithkline Beecham Plc Medicaments
WO2003048081A2 (en) 2001-12-04 2003-06-12 Bristol-Myers Squibb Company Glycinamides as factor xa inhibitors
EP2181996A1 (en) 2002-01-29 2010-05-05 Glaxo Group Limited Aminopiperidine derivatives
WO2003064431A2 (en) 2002-01-29 2003-08-07 Glaxo Group Limited Aminopiperidine compounds, process for their preparation, and pharmaceutical compositions containing them
AR040335A1 (es) 2002-06-26 2005-03-30 Glaxo Group Ltd Compuesto de ciclohexano o ciclohexeno, uso del mismo para preparar un medicamento, composicion farmaceutica que lo comprende, procedimiento y compuestos intermediarios de utilidad para preparar dicho compuesto
AR040336A1 (es) 2002-06-26 2005-03-30 Glaxo Group Ltd Compuesto de piperidina, uso del mismo para la fabricacion de un medicamento, composicion farmaceutica que lo comprende y procedimiento para preparar dicho compuesto
GB0217294D0 (en) 2002-07-25 2002-09-04 Glaxo Group Ltd Medicaments
FR2844270B1 (fr) 2002-09-11 2006-05-19 Aventis Pharma Sa Derives de la quinolyl propyl piperidine, leur procede et intermediaires de preparation et les compositions qui les contiennent
FR2844268B1 (fr) 2002-09-11 2004-10-22 Aventis Pharma Sa Derives de la quinolyl propyl piperidine, leurs procedes et intermediaires de preparation et les compositions qui les contiennent
CA2500320A1 (en) 2002-10-10 2004-04-29 Morphochem Aktiengesellschaft Fuer Kombinatorische Chemie Novel compounds with antibacterial activity
JP4704755B2 (ja) 2002-11-05 2011-06-22 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー 抗菌剤
DE60334016D1 (de) 2002-11-05 2010-10-14 Glaxo Group Ltd Antibakterielle mittel
AR042486A1 (es) 2002-12-18 2005-06-22 Glaxo Group Ltd Compuesto de quinolina y naftiridina halosustituido en la posicion 3, procedimiento para preparar el compuesto, composicion farmaceutica que lo comprende y su uso para preparar dicha composicion .
TW200507841A (en) 2003-03-27 2005-03-01 Glaxo Group Ltd Antibacterial agents
FR2852954B1 (fr) 2003-03-28 2006-07-14 Aventis Pharma Sa Derives de quinoleines-4-substituees, leurs procede et intermediaires de preparation et les compositions pharmaceutiques qui les contiennent
DE10316081A1 (de) 2003-04-08 2004-10-21 Morphochem AG Aktiengesellschaft für kombinatorische Chemie Neue Verbindungen mit antibakterieller Aktivität
WO2004104000A1 (ja) 2003-05-23 2004-12-02 Japan Tobacco Inc. トリサイクリック縮合環化合物およびその医薬用途
FR2858619B1 (fr) 2003-08-08 2006-12-22 Aventis Pharma Sa Derives de quinoleines-4-substituees, leurs procede et intermediaires de preparation et les compositions pharmaceutiques qui les contiennent
FR2867472B1 (fr) 2004-03-12 2008-07-18 Aventis Pharma Sa Derives de quinoleines-4-substituees, leurs procede et intermediaires de preparation et les compositions pharmaceutiques qui les contiennent
EP1796466A4 (en) 2004-06-15 2009-09-02 Glaxo Group Ltd ANTIBACTERIAL AGENTS
FR2872164B1 (fr) 2004-06-29 2006-11-17 Aventis Pharma Sa Derives de quinoleines-4-substituees, leur procede et intermediaires de preparation et les compositions pharmaceutiques qui les contiennent
US20070254872A1 (en) 2004-07-08 2007-11-01 Glaxo Group Limited Antibacterial Agents
US20080194547A1 (en) 2004-07-09 2008-08-14 Glaxo Group Limited Antibacterial Agents
EP1773343A4 (en) 2004-07-13 2009-05-13 Glaxo Group Ltd ANTIBACTERIAL AGENTS
JP2008507543A (ja) 2004-07-22 2008-03-13 グラクソ　グループ　リミテッド 抗細菌剤
ATE484509T1 (de) 2004-08-02 2010-10-15 Glaxo Group Ltd Antibakterielle mittel
WO2006020561A2 (en) 2004-08-09 2006-02-23 Glaxo Group Limited Antibacterial agents
DE102004041163A1 (de) 2004-08-25 2006-03-02 Morphochem Aktiengesellschaft für kombinatorische Chemie Neue Verbindungen mit antibakterieller Aktivität
JP4887297B2 (ja) 2004-09-24 2012-02-29 アクテリオン ファーマシューティカルズ リミテッド 新規二環式抗生物質
CN101039935B (zh) 2004-10-05 2011-04-20 埃科特莱茵药品有限公司 哌啶抗生素
JP5314244B2 (ja) 2004-10-27 2013-10-16 富山化学工業株式会社 新規な含窒素複素環化合物およびその塩
JP2008528587A (ja) 2005-01-25 2008-07-31 グラクソ グループ リミテッド 抗菌剤
US7605169B2 (en) 2005-01-25 2009-10-20 Glaxo Group Limited Antibacterial agents
EP1846418A4 (en) 2005-01-25 2009-12-23 Glaxo Group Ltd ANTIBACTERIAL ACTIVE SUBSTANCES
WO2006081178A2 (en) 2005-01-25 2006-08-03 Glaxo Group Limited Antibacterial agents
JP2008528604A (ja) 2005-01-25 2008-07-31 グラクソ グループ リミテッド 抗菌剤
WO2006099884A1 (en) 2005-03-24 2006-09-28 Actelion Percurex Ag Beta-aminoalcohol antibiotics
MX2007012234A (es) 2005-03-31 2008-03-18 Johnson & Johnson Compuestos de pirazol biciclico como agentes antibacterianos.
AR053602A1 (es) 2005-05-03 2007-05-09 Smithkline Beecham Corp Compuesto de 2- arilamino -4-oxo-1,3-tiazol-5(4h)- substituido, composicion farmaceutica que lo comprende, proceso para prepararla y uso del compuesto para preparar un medicamento
WO2006125974A1 (en) 2005-05-24 2006-11-30 Astrazeneca Ab Aminopiperidine quinolines and their azaisosteric analogues with antibacterial activity
US7981886B2 (en) 2005-05-25 2011-07-19 Actelion Pharmaceutical Ltd. Antibiotics derivatives
MY150958A (en) 2005-06-16 2014-03-31 Astrazeneca Ab Compounds for the treatment of multi-drug resistant bacterial infections
WO2006137485A1 (ja) 2005-06-24 2006-12-28 Toyama Chemical Co., Ltd. 新規な含窒素複素環化合物およびその塩
WO2007016610A2 (en) 2005-08-02 2007-02-08 Glaxo Group Limited Antibacterial agents
ES2340531T3 (es) 2005-10-21 2010-06-04 Glaxo Group Limited Compuestos triciclos peri-condensados utiles como agentes antibacterianos.
US7855201B2 (en) 2005-12-06 2010-12-21 Merck Sharp & Dohme. Corp. Morpholine carboxamide prokineticin receptor antagonists
DE602006013878D1 (de) 2005-12-22 2010-06-02 Glaxo Group Ltd Heterocyclische verbindungen, ihre herstellung und ihre verwendung als antibakterielle mittel
WO2007115947A1 (en) 2006-04-06 2007-10-18 Glaxo Group Limited Pyrrolo-quinoxalinone derivatives as antibacterials
WO2007118130A2 (en) 2006-04-06 2007-10-18 Glaxo Group Limited Antibacterial agents
GB0608263D0 (en) 2006-04-26 2006-06-07 Glaxo Group Ltd Compounds
WO2008006648A1 (en) 2006-06-09 2008-01-17 Glaxo Group Limited Substituted 1-methyl-1h-quinolin-2-ones and 1-methyl-1h-1,5-naphthyridin-2-ones as antibacterials
GB0613208D0 (en) 2006-07-03 2006-08-09 Glaxo Group Ltd Compounds
EP1992628A1 (en) 2007-05-18 2008-11-19 Glaxo Group Limited Derivatives and analogs of N-ethylquinolones and N-ethylazaquinolones
AU2008240764C1 (en) * 2007-04-20 2011-10-20 Glaxo Group Limited Tricyclic nitrogen containing compounds as antibacterial agents
CN102105473B (zh) * 2008-05-23 2013-05-08 葛兰素集团有限公司 三环含氮化合物及其作为抗菌剂的用途
WO2010043714A1 (en) * 2008-10-17 2010-04-22 Glaxo Group Limited Tricyclic nitrogen compounds used as antibacterials

Also Published As

Publication number Publication date
PE20170501A1 (es) 2017-04-27
PH12017500315A1 (en) 2017-07-10
EA031589B1 (ru) 2019-01-31
TW201618779A (zh) 2016-06-01
MX2017002321A (es) 2017-08-02
CA2958800C (en) 2020-10-27
CN106659717B (zh) 2019-09-06
BR112017003705B1 (pt) 2022-07-12
ES2759303T3 (es) 2020-05-08
CN110403939A (zh) 2019-11-05
KR20170043603A (ko) 2017-04-21
CL2017000391A1 (es) 2017-08-18
US20170304301A1 (en) 2017-10-26
CR20170069A (es) 2017-04-28
AU2015304847A1 (en) 2017-02-23
EP3639824A1 (en) 2020-04-22
US10702521B2 (en) 2020-07-07
US11229646B2 (en) 2022-01-25
EP3182973B1 (en) 2019-09-18
JP2017524029A (ja) 2017-08-24
WO2016027249A1 (en) 2016-02-25
AR101674A1 (es) 2017-01-04
AU2015304847B2 (en) 2018-10-25
EP3182973A1 (en) 2017-06-28
JP2019189629A (ja) 2019-10-31
JP6546654B2 (ja) 2019-07-17
IL250251A0 (en) 2017-03-30
DOP2017000049A (es) 2017-03-15
CA2958800A1 (en) 2016-02-25
EA201790442A1 (ru) 2017-08-31
SG11201700566SA (en) 2017-03-30
US20200330462A1 (en) 2020-10-22
CN106659717A (zh) 2017-05-10
CO2017001658A2 (es) 2017-07-19

Similar Documents

Publication Publication Date Title
BR112017003705A2 (pt) compostos contendo nitrogênio tricíclicos para o tratamento de infecção por neisseria gonorrhoea
EA201890204A1 (ru) Антибактериальные соединения
EA201691481A1 (ru) ИНГИБИТОРЫ C5a ДЛЯ ЛЕЧЕНИЯ ВИРУСНОЙ ПНЕВМОНИИ
EA201691440A1 (ru) Производные азепана и способы лечения инфекций гепатита в
TW201613901A (en) New compounds
MX2016013689A (es) Compuestos 4-amino-imidazoquinolina.
BR112017000714A2 (pt) indols funcionalizados e substituídos como agentes anti-câncer
EA202090098A1 (ru) Фармацевтические композиции терапевтически активных соединений
PH12017500401A1 (en) Therapeutic compounds as inhibitors of the orexin-1 receptor
MX2017002816A (es) Derivados de pirazolopiridina y su uso en terapia.
EA201692313A1 (ru) Производные индолизина в качестве ингибиторов фосфоинозитид-3-киназ
EA030204B8 (ru) Производные изоиндолина для применения в лечении вирусной инфекции
BR112016028316A2 (pt) composição farmacêutica oral de isotretinoina, seu processo de preparação e método de tratamento
IL261116A (en) A drug for the treatment of diabetic foot infections
BR112017016333A2 (pt) compostos anticâncer
AR103250A1 (es) Composiciones y métodos para tratar la hipercalemia
MX2016012758A (es) Composicion hiperosmolar de acido hialuronico.
BR112016020556A8 (pt) compostos, composição farmacêutica, método de modulação da atividade do receptor de grelina, método para o tratamento de uma doença e usos de um composto
BR112016029619A2 (pt) novas fluoroquinolonas e sesu usos no tratamento de infecções bacterianas
BR112017001963A2 (pt) composição farmacêutica oral, seu processo de preparação e método de tratamento
TR201903234T4 (tr) Parkinson hastalığının tedavisinde kullanılmaya yönelik dopamin içeren farmasötik çözelti.
RU2014154366A (ru) Применение пробиотического штамма микроорганизма enterococcus faecium l3 для лечения нейродегенеративных заболеваний
EA202190626A2 (ru) Комбинация тразодона и габапентина для лечения боли
BR112017019816A2 (pt) compostos, composição farmacêutica, método para o tratamento profilático ou terapêutico de doença dos rins e/ou fígado em um sujeito, e uso de um composto
EA201892675A1 (ru) Фармацевтическая композиция, содержащая этеплирсен

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 20/08/2015, OBSERVADAS AS CONDICOES LEGAIS